{
    "id": 21471,
    "fullName": "FGF19 negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "FGF19 negative indicates a lack of the FGF19 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9965,
        "geneSymbol": "FGF19",
        "terms": [
            "FGF19"
        ]
    },
    "variant": "negative",
    "createDate": "04/21/2016",
    "updateDate": "05/08/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10808,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived hepatocellular carcinoma cell lines without detectable Fgf19 expression did not respond to BLU9931 treatment in culture (PMID: 25776529).",
            "molecularProfile": {
                "id": 21998,
                "profileName": "FGF19 negative"
            },
            "therapy": {
                "id": 2509,
                "therapyName": "BLU9931",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2415,
                    "pubMedId": 25776529,
                    "title": "First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25776529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5911,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF19-negative hepatocellular carcinoma cell lines were insensitive to U3-1784 induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #3852).",
            "molecularProfile": {
                "id": 21998,
                "profileName": "FGF19 negative"
            },
            "therapy": {
                "id": 3980,
                "therapyName": "U3-1784",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5194,
                    "pubMedId": null,
                    "title": "U3-1784, a human anti-FGFR4 antibody for the treatment of cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=800c7dcf-322a-4e97-830b-0887c43f4108&cKey=4b473f86-5e89-431f-b228-b5a1a902ce34&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11976,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BLU-554 treatment resulted in tumor reduction in 58% (11/19, 1 complete response, 4 partial response, 6 stable disease) of Fgf19-positive hepatocellular carcinoma patients, but only in 15% (4/27, 4 stable disease) of Fgf19-negative patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 365O; NCT02508467).",
            "molecularProfile": {
                "id": 21998,
                "profileName": "FGF19 negative"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9941,
                    "pubMedId": null,
                    "title": "Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21998,
            "profileName": "FGF19 negative",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}